Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-07-19

AUTHORS

Gerardo Rosati, Stefano Cordio, Giuseppe Aprile, Alfredo Butera, Antonio Avallone, Giuseppe Di Lucca, Federica De Pauli, Hector Soto Parra, Giorgio Reggiardo, Roberto Bordonaro

ABSTRACT

Background Bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) when added to chemotherapy for metastatic colorectal cancer (mCRC). The hypothesis that bevacizumab discontinuation could lead to an angiogenesis flare and eventually to an accelerated tumor progression has not been confirmed in a recent large pooled analysis. Therefore the optimal duration of bevacizumab still remains undefined. Patients and methods PFS and OS were retrospectively analyzed in patients with previously untreated mCRC who received bevacizumab 5 mg/Kg and standard FOLFIRI regimen (leucovorin, infusional fluorouracil and irinotecan) up to a maximum of 12 cycles. Results Data from 209 patients were collected and analyzed. The median follow-up was 24 months. Fifty-five (26.3%) patients received at least 6 administrations and 114 (54.5%) received a maximum of 12 administrations of bevacizumab. Median exposure to bevacizumab was 148 days (4.9 months). Median PFS and OS were 10.7 months [95% confidence interval (CI) 9.2–12.2 months] and 31.6 months (95% CI 25.8–37.3 months), respectively. Overall objective response rate was 49.8% (95% CI 42.9–56.6) and the disease control rate 81.8%. Approximately 65% and 30% of patients received some form of second- and third-line therapy, respectively. The toxicity profile of bevacizumab was consistent with that documented in previous trials. Conclusions In this retrospective analysis remarkably long PFS and OS were obtained with a first-line therapy duration limited to a maximum of 12 cycles. Our data does not support a decreased PFS or increased mortality after discontinuation of bevacizumab in mCRC patients. More... »

PAGES

1978-1983

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-011-9721-6

DOI

http://dx.doi.org/10.1007/s10637-011-9721-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030635448

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21769636


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vitamin B Complex", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, S. Carlo Hospital, Via P. Petrone, 1, 85100, Potenza, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology Unit, S. Carlo Hospital, Via P. Petrone, 1, 85100, Potenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosati", 
        "givenName": "Gerardo", 
        "id": "sg:person.01362033743.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362033743.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Garibaldi Hospital, Catania, Italy", 
          "id": "http://www.grid.ac/institutes/grid.415299.2", 
          "name": [
            "Medical Oncology Unit, Garibaldi Hospital, Catania, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cordio", 
        "givenName": "Stefano", 
        "id": "sg:person.0636427643.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636427643.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, University Hospital, Udine, Italy", 
          "id": "http://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "Department of Medical Oncology, University Hospital, Udine, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aprile", 
        "givenName": "Giuseppe", 
        "id": "sg:person.01150115462.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150115462.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, S. Giovanni di Dio Hospital, Agrigento, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology Unit, S. Giovanni di Dio Hospital, Agrigento, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Butera", 
        "givenName": "Alfredo", 
        "id": "sg:person.01243412173.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243412173.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastrointestinal Medical Oncology, National Cancer Institute, Naples, Italy", 
          "id": "http://www.grid.ac/institutes/grid.508451.d", 
          "name": [
            "Department of Gastrointestinal Medical Oncology, National Cancer Institute, Naples, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Avallone", 
        "givenName": "Antonio", 
        "id": "sg:person.0661315002.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661315002.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Civil Hospital, Saronno, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology Unit, Civil Hospital, Saronno, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Lucca", 
        "givenName": "Giuseppe", 
        "id": "sg:person.01067104643.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067104643.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, University Hospital, Udine, Italy", 
          "id": "http://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "Department of Medical Oncology, University Hospital, Udine, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Pauli", 
        "givenName": "Federica", 
        "id": "sg:person.01135220043.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135220043.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Garibaldi Hospital, Catania, Italy", 
          "id": "http://www.grid.ac/institutes/grid.415299.2", 
          "name": [
            "Medical Oncology Unit, Garibaldi Hospital, Catania, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Parra", 
        "givenName": "Hector Soto", 
        "id": "sg:person.013545343107.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013545343107.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Biostatistic Unit Medi Service, Genova, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Biostatistic Unit Medi Service, Genova, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reggiardo", 
        "givenName": "Giorgio", 
        "id": "sg:person.01251446443.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251446443.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Garibaldi Hospital, Catania, Italy", 
          "id": "http://www.grid.ac/institutes/grid.415299.2", 
          "name": [
            "Medical Oncology Unit, Garibaldi Hospital, Catania, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bordonaro", 
        "givenName": "Roberto", 
        "id": "sg:person.01226343067.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226343067.28"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2011-07-19", 
    "datePublishedReg": "2011-07-19", 
    "description": "Background Bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) when added to chemotherapy for metastatic colorectal cancer (mCRC). The hypothesis that bevacizumab discontinuation could lead to an angiogenesis flare and eventually to an accelerated tumor progression has not been confirmed in a recent large pooled analysis. Therefore the optimal duration of bevacizumab still remains undefined. Patients and methods PFS and OS were retrospectively analyzed in patients with previously untreated mCRC who received bevacizumab 5\u00a0mg/Kg and standard FOLFIRI regimen (leucovorin, infusional fluorouracil and irinotecan) up to a maximum of 12 cycles. Results Data from 209 patients were collected and analyzed. The median follow-up was 24\u00a0months. Fifty-five (26.3%) patients received at least 6 administrations and 114 (54.5%) received a maximum of 12 administrations of bevacizumab. Median exposure to bevacizumab was 148\u00a0days (4.9\u00a0months). Median PFS and OS were 10.7\u00a0months [95% confidence interval (CI) 9.2\u201312.2\u00a0months] and 31.6\u00a0months (95% CI 25.8\u201337.3\u00a0months), respectively. Overall objective response rate was 49.8% (95% CI 42.9\u201356.6) and the disease control rate 81.8%. Approximately 65% and 30% of patients received some form of second- and third-line therapy, respectively. The toxicity profile of bevacizumab was consistent with that documented in previous trials. Conclusions In this retrospective analysis remarkably long PFS and OS were obtained with a first-line therapy duration limited to a maximum of 12 cycles. Our data does not support a decreased PFS or increased mortality after discontinuation of bevacizumab in mCRC patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-011-9721-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "metastatic colorectal cancer", 
      "discontinuation of bevacizumab", 
      "overall survival", 
      "colorectal cancer", 
      "untreated metastatic colorectal cancer", 
      "median progression-free survival", 
      "overall objective response rate", 
      "decreased progression-free survival", 
      "longer progression-free survival", 
      "large pooled analysis", 
      "standard FOLFIRI regimen", 
      "retrospective Italian study", 
      "objective response rate", 
      "third-line therapy", 
      "first-line therapy", 
      "administration of bevacizumab", 
      "accelerated tumor progression", 
      "Background Bevacizumab", 
      "FOLFIRI regimen", 
      "mCRC patients", 
      "therapy duration", 
      "pooled analysis", 
      "retrospective analysis", 
      "bevacizumab", 
      "median exposure", 
      "toxicity profile", 
      "patients", 
      "response rate", 
      "optimal duration", 
      "tumor progression", 
      "discontinuation", 
      "Italian study", 
      "previous trials", 
      "months", 
      "therapy", 
      "cancer", 
      "administration", 
      "survival", 
      "result data", 
      "duration", 
      "FOLFIRI", 
      "regimen", 
      "chemotherapy", 
      "mortality", 
      "progression", 
      "trials", 
      "exposure", 
      "days", 
      "conclusion", 
      "data", 
      "study", 
      "rate", 
      "cycle", 
      "flares", 
      "analysis", 
      "hypothesis", 
      "profile", 
      "Kg", 
      "maximum", 
      "form", 
      "angiogenesis flare", 
      "recent large pooled analysis", 
      "methods PFS", 
      "disease control rate 81.8", 
      "control rate 81.8", 
      "rate 81.8", 
      "first-line therapy duration"
    ], 
    "name": "Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study", 
    "pagination": "1978-1983", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030635448"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-011-9721-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21769636"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-011-9721-6", 
      "https://app.dimensions.ai/details/publication/pub.1030635448"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_539.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-011-9721-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9721-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9721-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9721-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-011-9721-6'


 

This table displays all metadata directly associated to this object as RDF triples.

288 TRIPLES      21 PREDICATES      114 URIs      106 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-011-9721-6 schema:about N02227657556f4179b7c11de4fb60c5c1
2 N15594c2d6bb4483597eec87543a443d4
3 N24e18b3b8bb54e0fa4831ac2262fc7db
4 N2deb698d4dfd4334b2b969222577032c
5 N34cd7e099e714ed5a0bf03ee50aff8c8
6 N3d9513324555406a995dd2362214587c
7 N47600902d97d45b5a2074f75e189535e
8 N512f59f04c234f8187da82c072b01fb8
9 N5e6b086d2aa1489faa3f3c6bc935ffb7
10 N5fff1f86753b484c95abd01b572457c4
11 N6ad660e687a443edb798e7aac14bd77e
12 N7492334f92b64562a9f51bbcde39d7b0
13 N953302e1f2f84809881ded1ec0ae02bd
14 N96380d8607fc4b40baed85fd15cea309
15 N9a814bb85cc940138a7c960d9032d20e
16 Na0a666abb7c9408b9b1c93845b8fb607
17 Nb01a1f746d0c472188293153194c4251
18 Nbdf51345f6e34598b74b3d8f00b99980
19 Nd842208a0ed448a4818ff11b6fe9318c
20 Nf606639dac2c457da35169a27d2db394
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author N02259ef3dfe54ce9b6cf10c5c4412bb5
24 schema:datePublished 2011-07-19
25 schema:datePublishedReg 2011-07-19
26 schema:description Background Bevacizumab significantly improves progression-free survival (PFS) and overall survival (OS) when added to chemotherapy for metastatic colorectal cancer (mCRC). The hypothesis that bevacizumab discontinuation could lead to an angiogenesis flare and eventually to an accelerated tumor progression has not been confirmed in a recent large pooled analysis. Therefore the optimal duration of bevacizumab still remains undefined. Patients and methods PFS and OS were retrospectively analyzed in patients with previously untreated mCRC who received bevacizumab 5 mg/Kg and standard FOLFIRI regimen (leucovorin, infusional fluorouracil and irinotecan) up to a maximum of 12 cycles. Results Data from 209 patients were collected and analyzed. The median follow-up was 24 months. Fifty-five (26.3%) patients received at least 6 administrations and 114 (54.5%) received a maximum of 12 administrations of bevacizumab. Median exposure to bevacizumab was 148 days (4.9 months). Median PFS and OS were 10.7 months [95% confidence interval (CI) 9.2–12.2 months] and 31.6 months (95% CI 25.8–37.3 months), respectively. Overall objective response rate was 49.8% (95% CI 42.9–56.6) and the disease control rate 81.8%. Approximately 65% and 30% of patients received some form of second- and third-line therapy, respectively. The toxicity profile of bevacizumab was consistent with that documented in previous trials. Conclusions In this retrospective analysis remarkably long PFS and OS were obtained with a first-line therapy duration limited to a maximum of 12 cycles. Our data does not support a decreased PFS or increased mortality after discontinuation of bevacizumab in mCRC patients.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf N0668bce86c214fe6b5d29558673f66df
31 N6acdcdc94e684962904db467a85dc811
32 sg:journal.1094201
33 schema:keywords Background Bevacizumab
34 FOLFIRI
35 FOLFIRI regimen
36 Italian study
37 Kg
38 accelerated tumor progression
39 administration
40 administration of bevacizumab
41 analysis
42 angiogenesis flare
43 bevacizumab
44 cancer
45 chemotherapy
46 colorectal cancer
47 conclusion
48 control rate 81.8
49 cycle
50 data
51 days
52 decreased progression-free survival
53 discontinuation
54 discontinuation of bevacizumab
55 disease control rate 81.8
56 duration
57 exposure
58 first-line therapy
59 first-line therapy duration
60 flares
61 form
62 hypothesis
63 large pooled analysis
64 longer progression-free survival
65 mCRC patients
66 maximum
67 median exposure
68 median progression-free survival
69 metastatic colorectal cancer
70 methods PFS
71 months
72 mortality
73 objective response rate
74 optimal duration
75 overall objective response rate
76 overall survival
77 patients
78 pooled analysis
79 previous trials
80 profile
81 progression
82 progression-free survival
83 rate
84 rate 81.8
85 recent large pooled analysis
86 regimen
87 response rate
88 result data
89 retrospective Italian study
90 retrospective analysis
91 standard FOLFIRI regimen
92 study
93 survival
94 therapy
95 therapy duration
96 third-line therapy
97 toxicity profile
98 trials
99 tumor progression
100 untreated metastatic colorectal cancer
101 schema:name Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study
102 schema:pagination 1978-1983
103 schema:productId N731d9e6b0ad34cb98b0e23b6f1604744
104 Ncd54515c08cb4758a920598b60a08b36
105 Neeee14fcfee546d0a7f0b49f1c49f1d9
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030635448
107 https://doi.org/10.1007/s10637-011-9721-6
108 schema:sdDatePublished 2021-12-01T19:25
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N683f8966e5ea43c5adaafe801ef60060
111 schema:url https://doi.org/10.1007/s10637-011-9721-6
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N02227657556f4179b7c11de4fb60c5c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Irinotecan
117 rdf:type schema:DefinedTerm
118 N02259ef3dfe54ce9b6cf10c5c4412bb5 rdf:first sg:person.01362033743.92
119 rdf:rest Nbd5a2eb54d634afe999bbe22043162e7
120 N0668bce86c214fe6b5d29558673f66df schema:volumeNumber 30
121 rdf:type schema:PublicationVolume
122 N0829ecc016134eb3b80e5e4b38fd54b1 rdf:first sg:person.01243412173.62
123 rdf:rest Nbb52a259fbb94cebaf9bfe454eba8386
124 N15594c2d6bb4483597eec87543a443d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 N1e54d5e5e5d6449fb00800308010424b rdf:first sg:person.01226343067.28
128 rdf:rest rdf:nil
129 N24e18b3b8bb54e0fa4831ac2262fc7db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Antibodies, Monoclonal, Humanized
131 rdf:type schema:DefinedTerm
132 N2deb698d4dfd4334b2b969222577032c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Antineoplastic Combined Chemotherapy Protocols
134 rdf:type schema:DefinedTerm
135 N34cd7e099e714ed5a0bf03ee50aff8c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Male
137 rdf:type schema:DefinedTerm
138 N3d9513324555406a995dd2362214587c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N47600902d97d45b5a2074f75e189535e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Retrospective Studies
143 rdf:type schema:DefinedTerm
144 N51089819844d4a53977786c198049ca5 rdf:first sg:person.01135220043.21
145 rdf:rest N929c1813878e4d3398954e3489d91da4
146 N512f59f04c234f8187da82c072b01fb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Follow-Up Studies
148 rdf:type schema:DefinedTerm
149 N52afea65c16d4d2aa1d6d16e317f8400 rdf:first sg:person.01251446443.14
150 rdf:rest N1e54d5e5e5d6449fb00800308010424b
151 N5e6b086d2aa1489faa3f3c6bc935ffb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Bevacizumab
153 rdf:type schema:DefinedTerm
154 N5fff1f86753b484c95abd01b572457c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Adult
156 rdf:type schema:DefinedTerm
157 N683f8966e5ea43c5adaafe801ef60060 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 N6acdcdc94e684962904db467a85dc811 schema:issueNumber 5
160 rdf:type schema:PublicationIssue
161 N6ad660e687a443edb798e7aac14bd77e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Leucovorin
163 rdf:type schema:DefinedTerm
164 N731d9e6b0ad34cb98b0e23b6f1604744 schema:name doi
165 schema:value 10.1007/s10637-011-9721-6
166 rdf:type schema:PropertyValue
167 N7492334f92b64562a9f51bbcde39d7b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Female
169 rdf:type schema:DefinedTerm
170 N912cd074c58f4e329310ca9f5c708621 rdf:first sg:person.01150115462.24
171 rdf:rest N0829ecc016134eb3b80e5e4b38fd54b1
172 N929c1813878e4d3398954e3489d91da4 rdf:first sg:person.013545343107.29
173 rdf:rest N52afea65c16d4d2aa1d6d16e317f8400
174 N953302e1f2f84809881ded1ec0ae02bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Disease-Free Survival
176 rdf:type schema:DefinedTerm
177 N96380d8607fc4b40baed85fd15cea309 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Cohort Studies
179 rdf:type schema:DefinedTerm
180 N9a814bb85cc940138a7c960d9032d20e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Fluorouracil
182 rdf:type schema:DefinedTerm
183 Na0a666abb7c9408b9b1c93845b8fb607 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Vitamin B Complex
185 rdf:type schema:DefinedTerm
186 Nb01a1f746d0c472188293153194c4251 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Camptothecin
188 rdf:type schema:DefinedTerm
189 Nb208d1f6d7d74c2086b35a531d4ff929 rdf:first sg:person.01067104643.74
190 rdf:rest N51089819844d4a53977786c198049ca5
191 Nbb52a259fbb94cebaf9bfe454eba8386 rdf:first sg:person.0661315002.90
192 rdf:rest Nb208d1f6d7d74c2086b35a531d4ff929
193 Nbd5a2eb54d634afe999bbe22043162e7 rdf:first sg:person.0636427643.11
194 rdf:rest N912cd074c58f4e329310ca9f5c708621
195 Nbdf51345f6e34598b74b3d8f00b99980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Aged
197 rdf:type schema:DefinedTerm
198 Ncd54515c08cb4758a920598b60a08b36 schema:name dimensions_id
199 schema:value pub.1030635448
200 rdf:type schema:PropertyValue
201 Nd842208a0ed448a4818ff11b6fe9318c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Drug Administration Schedule
203 rdf:type schema:DefinedTerm
204 Neeee14fcfee546d0a7f0b49f1c49f1d9 schema:name pubmed_id
205 schema:value 21769636
206 rdf:type schema:PropertyValue
207 Nf606639dac2c457da35169a27d2db394 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Colorectal Neoplasms
209 rdf:type schema:DefinedTerm
210 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
211 schema:name Medical and Health Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
214 schema:name Oncology and Carcinogenesis
215 rdf:type schema:DefinedTerm
216 sg:journal.1094201 schema:issn 0167-6997
217 1573-0646
218 schema:name Investigational New Drugs
219 schema:publisher Springer Nature
220 rdf:type schema:Periodical
221 sg:person.01067104643.74 schema:affiliation grid-institutes:None
222 schema:familyName Di Lucca
223 schema:givenName Giuseppe
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067104643.74
225 rdf:type schema:Person
226 sg:person.01135220043.21 schema:affiliation grid-institutes:grid.411492.b
227 schema:familyName De Pauli
228 schema:givenName Federica
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135220043.21
230 rdf:type schema:Person
231 sg:person.01150115462.24 schema:affiliation grid-institutes:grid.411492.b
232 schema:familyName Aprile
233 schema:givenName Giuseppe
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150115462.24
235 rdf:type schema:Person
236 sg:person.01226343067.28 schema:affiliation grid-institutes:grid.415299.2
237 schema:familyName Bordonaro
238 schema:givenName Roberto
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226343067.28
240 rdf:type schema:Person
241 sg:person.01243412173.62 schema:affiliation grid-institutes:None
242 schema:familyName Butera
243 schema:givenName Alfredo
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01243412173.62
245 rdf:type schema:Person
246 sg:person.01251446443.14 schema:affiliation grid-institutes:None
247 schema:familyName Reggiardo
248 schema:givenName Giorgio
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251446443.14
250 rdf:type schema:Person
251 sg:person.013545343107.29 schema:affiliation grid-institutes:grid.415299.2
252 schema:familyName Parra
253 schema:givenName Hector Soto
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013545343107.29
255 rdf:type schema:Person
256 sg:person.01362033743.92 schema:affiliation grid-institutes:None
257 schema:familyName Rosati
258 schema:givenName Gerardo
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362033743.92
260 rdf:type schema:Person
261 sg:person.0636427643.11 schema:affiliation grid-institutes:grid.415299.2
262 schema:familyName Cordio
263 schema:givenName Stefano
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636427643.11
265 rdf:type schema:Person
266 sg:person.0661315002.90 schema:affiliation grid-institutes:grid.508451.d
267 schema:familyName Avallone
268 schema:givenName Antonio
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661315002.90
270 rdf:type schema:Person
271 grid-institutes:None schema:alternateName Biostatistic Unit Medi Service, Genova, Italy
272 Medical Oncology Unit, Civil Hospital, Saronno, Italy
273 Medical Oncology Unit, S. Carlo Hospital, Via P. Petrone, 1, 85100, Potenza, Italy
274 Medical Oncology Unit, S. Giovanni di Dio Hospital, Agrigento, Italy
275 schema:name Biostatistic Unit Medi Service, Genova, Italy
276 Medical Oncology Unit, Civil Hospital, Saronno, Italy
277 Medical Oncology Unit, S. Carlo Hospital, Via P. Petrone, 1, 85100, Potenza, Italy
278 Medical Oncology Unit, S. Giovanni di Dio Hospital, Agrigento, Italy
279 rdf:type schema:Organization
280 grid-institutes:grid.411492.b schema:alternateName Department of Medical Oncology, University Hospital, Udine, Italy
281 schema:name Department of Medical Oncology, University Hospital, Udine, Italy
282 rdf:type schema:Organization
283 grid-institutes:grid.415299.2 schema:alternateName Medical Oncology Unit, Garibaldi Hospital, Catania, Italy
284 schema:name Medical Oncology Unit, Garibaldi Hospital, Catania, Italy
285 rdf:type schema:Organization
286 grid-institutes:grid.508451.d schema:alternateName Department of Gastrointestinal Medical Oncology, National Cancer Institute, Naples, Italy
287 schema:name Department of Gastrointestinal Medical Oncology, National Cancer Institute, Naples, Italy
288 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...